Napo Pharm.Regs Share Discussion Threads

[monis] 19/6/2008 15:49

Nice tick up, looks like it's on the move again.

[monis] 19/6/2008 15:47

50,000 buy

[monis] 17/6/2008 16:02

12p now to buy 10,500 shares. Above the offer price.

[monis] 16/6/2008 16:38

10,000 buy sneaked through at 4.30.

[monis] 16/6/2008 08:29

Also recent buys appear not to have been reported which I can confirm.

[monis] 16/6/2008 08:09

Some large buys went through this time last week which has not been commented on. They were in the afternoon so could be from the states.

Only bodes well imho.

[monis] 21/5/2008 23:49

I'll check it out.

[abc125] 21/5/2008 22:36

monis....you seem like the only one posting on this thread. Sometimes its the quietest threads that give the biggest returns....I notice this has 5 bagged from its recent lows. Well done.

I'm into Litcomp (LIN), another quiet thread....but with bags of potential.

[monis] 19/5/2008 11:56

Good question, not entirely sure. I think they are the same company but listing a different type of share. Your broker could clarify. DYOR.

[flojo] 19/5/2008 11:48

What are NAPU ?

[monis] 19/5/2008 11:36

Re adjusting NAPU up today. Keeping it in line with us at NAPL I suppose.

[monis] 16/5/2008 08:09

Codes the companies broker (dyor) is on the bid which bodes very well imho.

[monis] 15/5/2008 19:34

This TFN explains the link up between the two companies.


Napo Pharma says recent shr price drop undervalues co, disregards trial results

LONDON (Thomson Financial) - Napo Pharmaceuticals Inc. said the recent stock
price drop dramatically undervalues the company, adding the fall in its share
price places an unrealistic value on Napo and disregards the recently announced
trial results.
The pharma company had earlier said it received positive results from Phase
2 trials for its crofelemer (CRO-ID )treatment of acute adult infectious
diarrhoea which was conducted by its licensee partner, Glenmark Pharmaceuticals
Ltd.
Glenmark reported crofelemer was well tolerated and showed significant
improvements in all the primary endpoints -- stool weight, duration, frequency
and consistency; additional endpoints included degree of patient dehydration and
reduction in gastrointestinal index score.

[monis] 15/5/2008 19:27

Glenmark, Napo's partner seems to be doing very well.

A bit of research.


India's Glenmark Pharma Q4 net more than triples

BANGALORE (Thomson Financial) - India's Glenmark Pharmaceuticals Ltd. said
its fourth-quarter net profit more than tripled on higher incomes, a milestone
payment of $15 million from Forest Laboratories Inc., and the good performance
of its U.S. business.
For the three months ended March 31, 2008, the Indian pharmaceutical company
posted a consolidated net profit of 2.19 billion rupees, compared with 622.03
million rupees a year earlier as consolidated revenues rose about 62.6 percent
to 5.82 billion rupees.
Glenmark Generics Inc., its U.S. unit, posted a revenue growth of 144.30
percent to 1.96 million rupees from 803.35 million rupees earlier.
On Feb. 6, Glenmark Pharmaceuticals said its Swiss unit received a $15
million milestone payment from Forest Laboratories Inc. got U.S. Food and Drug
Administration (FDA) approval to initiate an additional phase II study for the
drug Oglemilast (GRC 3886), used in the treatment of chronic obstructive
pulmonary diseases (Copd) and asthma. Forest Labs is Glenmark Pharma's U.S.
partner for Oglemilast.
The company also said its monoclonal antibody GBR 500 has completed the
crucial IND-enabling preclinical studies and added that it intends to file an
investigational new drug application to begin phase I trials with the FDA by
August. The company expects the trial will be completed this fiscal year.
Chief executive Glenn Saldanha said: "We are also happy to take our
biologics program forward with GBR 500 moving into phase I trials. This is
Glenmark's first new biological entity (NBE) to enter the clinics from our
pipeline of 13 NCEs (new chemical entities) and NBEs, and demonstrates our
steady progress in the drug discovery space."
The company also reported a net profit of 6.312 billion rupees for the year
ended March 31, 2008 compared with a net profit of 3.10 billion rupees a year
earlier. Total income rose to 20.23 billion rupees from 12.32 billion rupees
earlier.

[monis] 15/5/2008 18:53

What's interesting is that Codes the market makers on the bid to my knowlwdge (DYOR) are the companies brokers, which is a very good sign imo.

[monis] 14/5/2008 21:36

Again just buys today.

[monis] 14/5/2008 16:07

If it took 10 mins it would suggest to me that they are short of stock.

[flojo] 14/5/2008 15:07

Dont know just kept saying pending or working deal,what do you think.

[monis] 14/5/2008 14:59

flo jo What was the reason why it took 10mins?

[monis] 14/5/2008 14:55

If phase 3 is completed and succesful (previous results have been good) peak sales for the US alone are predicted to be $300m. That is why they are undervalued imho. DYOR.

[flojo] 14/5/2008 14:52

The mms have spare stock ,the 4000 was mine that took ten mis to get.

[monis] 14/5/2008 14:42

flo-jo - how do I know what? Why they turned down giving you shares at 12.5p? The reason is that I believe the company is still massively undervalued, imo. DYOR.

[monis] 14/5/2008 14:38

double 6- I don't know about that, I would say quite the opposite as a 34,000 buy has gone through and a 4000 buy has gone through, I would expect the price to tick up again imminently.